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The Hippo signaling pathway is an evolutionarily conserved developmental network vital 
for the regulation of organ size, tissue homeostasis, repair and regeneration, and cell fate. 
The Hippo pathway has also been shown to have tumor suppressor properties. Hippo 
transduction involves a series of kinases and scaffolding proteins that are intricately 
connected to proteins in developmental cascades and in the tissue microenvironment. 
This network governs the downstream Hippo transcriptional co-activators, YAP and 
TAZ, which bind to and activate the output of TEADs, as well as other transcription 
factors responsible for cellular proliferation, self-renewal, differentiation, and survival. 
Surprisingly, there are few oncogenic mutations within the core components of the Hippo 
pathway. Instead, dysregulated Hippo signaling is a versatile accomplice to commonly 
mutated cancer pathways. For example, YAP and TAZ can be activated by oncogenic 
signaling from other pathways, or serve as co-activators for classical oncogenes. 
Emerging evidence suggests that Hippo signaling couples cell density and cytoskeletal 
structural changes to morphogenic signals and conveys a mesenchymal phenotype. 
While much of Hippo biology has been described in epithelial cell systems, it is clear that 
dysregulated Hippo signaling also contributes to malignancies of mesenchymal origin. 
This review will summarize the known molecular alterations within the Hippo pathway in 
sarcomas and highlight how several pharmacologic compounds have shown activity in 
modulating Hippo components, providing proof-of-principle that Hippo signaling may be 
harnessed for therapeutic application in sarcomas.
Keywords: Hippo, sarcoma, osteosarcoma, ewing sarcoma, rhabdomyosarcoma, mesenchymal, targeted 
therapy, pediatric cancers
introduction
Overview of Pediatric Sarcomas
Sarcomas account for ~1% of all malignancies, but occur with higher frequency in children compared 
to adults, comprising ~15% of all childhood malignancies (1). The mainstay of treatment includes 
combining primary tumor control with surgery and/or radiation and systemic chemotherapy. While 
survival rates for localized sarcomas have improved to >70%, children with metastatic or recurrent 
disease continue to have dismal outcomes (2, 3).
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Malignant bone and soft-tissue sarcomas arise in connective 
tissues (including bone, fat, muscle, blood vessels, deep skin 
tissues, nerves, and cartilage) and represent a histologically 
and molecularly heterogeneous group of tumors. Although 
the precise cell of origin of most of these tumors is not 
known, sarcomas are thought to develop as a result of genetic 
alterations in mesenchymal progenitor cells. While older 
adult patients often develop sarcomas with complex genetic 
karyotypes, there are relatively few genetic mutations driving 
tumorigenesis for the majority of childhood sarcomas, with 
the exception of some characteristic chromosomal transloca-
tions. In cases where the underlying molecular pathogenesis 
has been identified, this has not translated into improvements 
in survival rates for those patients with advanced or aggressive 
tumors, as many of the molecular drivers have not been able to 
pharmacologically modulated (2, 3). Discovering therapeuti-
cally targetable proteins that may be collaborating with such 
tumorigenic drivers is a promising new frontier for molecular 
oncology.
Overview of Hippo Signaling
The delineation of the Hippo pathway began in 2003 with 
identification of the Drosophila hippo gene. Hippo loss-of-
function phenotypes were described concurrently by the Pan and 
Hariharan laboratories while screening for genes that negatively 
regulate tissue growth (4, 5). Subsequent studies unveiled Hippo 
signaling as an evolutionarily conserved cascade consisting of 
adaptor proteins and inhibitory kinases that regulate Yorkie, 
a pro-growth transcriptional regulator (6–8). Hippo signal-
ing is highly conserved between Drosophila and mammals, 
and homologous pathway components across species are well 
described (9, 10). For this review, focus will be on mammalian 
Hippo signaling.
As shown in Figure  1, the mammalian Hippo pathway 
relays plasma membrane and cytoplasmic signals into the 
nucleus, where it regulates the expression of a diverse group of 
target genes that control essential cellular processes, including 
proliferation, differentiation, and apoptosis. Canonical Hippo 
transduction involves serine/threonine kinases mammalian 
STE20-like protein kinase 1/2 (MST1/2, which are homologs 
of Drosophila Hippo) (4, 5, 11, 12) and large tumor suppressor 
homolog 1/2 (LATS1/2) (7, 13, 14), which, in conjunction with 
adaptor proteins Salvador homolog 1 (SAV1) (12) and Mob 
kinase activator 1 (MOB1) (15), phosphorylate and inhibit the 
transcriptional co-activators Yes-associated protein 1 (YAP, a 
homolog of Yorkie) and transcriptional co-activator with PDZ-
binding motif (TAZ) [also known as WW domain-containing 
transcription regulator 1, WWTR1] (16). The Hippo pathway is 
“ON” when MST1/2 and LATS1/2 kinases are active. Through 
an interaction between the PPxY (PY) motifs of LATS1/2 and 
the WW domains of YAP and TAZ, activated LATS1/2 lead 
to phosphorylation of YAP and TAZ, which results in YAP/
TAZ cytoplasmic retention and β-TRCP (β-transducin repeat-
containing E3 ubiquitin protein ligase)-dependent proteasomal 
degradation (9, 10). When Hippo signaling is inactive or “OFF”, 
YAP and TAZ are localized to the nucleus, where they serve 
as transcriptional co-activators for TEA domain-containing 
sequence-specific transcription factors (TEADs) (17–21) as well 
as other transcription factors (16).
Regulation of the Hippo Pathway
Much of our understanding of Hippo regulation comes from 
studies performed in epithelial tissue. In this context, the 
transcriptional activities of YAP and TAZ are regulated by four 
interconnected inputs: (1) plasma membrane proteins, which 
complex with YAP and TAZ directly to sequester them at cell–cell 
junctions; (2) upstream adaptor proteins, which activate core 
Hippo kinases to ultimately phosphorylate and repress YAP and 
TAZ; (3) regulatory cross-talk from other signaling pathways; 
FiGURe 1 | Schematic representation of the mammalian Hippo 
signaling cascade. Canonical Hippo transduction involves MST1/2 and 
LATS1/2 kinases, which, in conjunction with SAV1 and MOB1, 
phosphorylate, and inhibit the transcriptional co-activators YAP and TAZ. 
Regulation of YAP and TAZ are governed by plasma membrane proteins, 
cytoskeletal adaptor proteins, regulatory cross-talk from other signaling 
pathways, and intrinsic and extrinsic mechanical cues with the actin 
cytoskeleton. For simplicity, not all the known protein–protein interactions 
and regulators of Hippo signaling are represented. When Hippo signaling 
is “OFF”, YAP/TAZ translocate to the nucleus to serve as transcriptional 
co-activators for TEADs as well as other transcription factors (only a few 
of which are represented here) involved in cellular proliferation, 
differentiation, self-renewal, and apoptosis. See text for additional 
details.
Abbreviations: AMOT, angiomotin; APC, adenomatous polyposis coli; ARMS, 
alveolar rhabdomyosarcoma; β-TRCP, β-transducin repeat-containing E3 ubiq-
uitin protein ligase; BMI-1, B-lymphoma Mo-MLV insertion region 1 homolog; 
BMP2, bone morphogenetic protein 2; BRAF, v-raf murine sarcoma viral oncogene 
homolog B; cAMP, adenylyl cyclase pathway; CD44, CD44 antigen; CDKN2A, 
cyclin-dependent kinase inhibitor 2A; ChIP-Seq, chromatin immunoprecipitation 
followed by high-throughput DNA sequencing; CRB, crumbs complex proteins; 
CTGF, connective tissue growth factor; dLats, large tumor suppressor (or warts); 
DMBA, 9,10-dimethyl-1,2-benzanthracene; DVL, disheveled; ECM, extracellular 
matrix; EGFR, epidermal growth factor receptor; EHE, epithelioid hemangioen-
dothelioma; ERK, extracellular signal-regulated kinases; ERMS, embryonal rhab-
domyosarcoma; EWS, Ewing sarcoma; FAT4, FAT tumor suppressor homolog 4; 
FOXM1, transcription factor forkhead box M1; GEMM, genetically engineered 
mouse model; GPCRs, G protein-coupled receptors; HMG-CoA, 3-hydroxy-
3-methylglutaryl-coenzyme A; hTERT, telomerase reverse transcriptase; ID2, 
inhibitor of DNA binding 2; KIBRA, kidney and brain protein; LATS1/2, large 
tumor suppressor homolog 1/2; LLGL1, lethal giant larvae homolog 1; MAPK, 
mitogen-activated protein kinase; MARK1, MAP/microtubule affinity-regulating 
kinase 1; MCAT, muscle CAT elements; MDM2, mouse double minute 2; MEF2, 
myocyte enhancer factor 2; MEK, MAPK kinase; MMP-9, matrix metallopeptidase 
9; MOB1, Mob kinase activator 1; MRFs, myogenic regulatory factor family; MSC, 
mesenchymal stem cell; MST1/2, serine/threonine kinases mammalian STE20-
like protein kinase 1/2; mTOR, mechanistic target of rapamycin; MYCN, v-myc 
avian myelocytomatosis viral oncogene neuroblastoma derived homolog; Myf5, 
myogenic factor 5; MyHC, myosin heavy chain; MyoD, myogenic differentiation 1; 
NF2, neurofibromin 2 (or Merlin); NRSTS, non-rhabdomyosarcoma soft-tissue 
sarcoma; NSCLC, non-small cell lung cancer; OCT4, octamer-binding transcrip-
tion factor-4; OS, osteosarcoma; p16INK4A, prototypic INK4 protein; PCNA, 
proliferating cell nuclear antigen; PDE, phosphodiesterase; PKA, protein kinase 
A; PKN1, protein kinase N1; PP1A, protein phosphatase 1, catalytic subunit, 
alpha isozyme; PP2A, protein phosphatase 2, regulatory subunit B, delta1; PPARγ, 
peroxisome proliferator-activated receptor gamma; RAF, v-raf murine sarcoma 
viral oncogene homolog; RAS, rat sarcoma viral oncogene homolog; RASSFs, 
Ras-association domain-containing family of proteins; RB1, retinoblastoma 1; 
RHO, rhodopsin; RMS, rhabdomyosarcoma; ROCK1, Rho-associated, coiled-coil 
containing protein kinase 1; RUNX2, runt-related transcription factor 2; SARAH 
domain, Salvador-Rassf-Hpo binding domain; SAV1, salvador homolog  1; 
SMADs, mothers against decapentaplegic proteins; Snai1/2, snail family zinc 
finger 1/2; SOX2, SRY (sex determining region Y)-box 2; STS, soft-tissue sarcoma; 
TAO-1, thousand and one amino acid protein 1; TAZ, transcriptional co-activator 
with PDZ-binding motif (or WWTR1); TCGA, The Cancer Genome Atlas; 
TEADs, TEA domain-containing sequence-specific transcription factors; TGFβ, 
transforming growth factor beta; TNF-α, tumor necrosis factor alpha; TP53, tumor 
protein p53; TP73, tumor protein p73; Twist1, twist family bHLH transcription 
factor 1; UVB, ultraviolet radiation B; VGLL3, vestigial-like 3; WNT, wingless-type 
MMTV integration site family; YAP, yes-associated protein 1.
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nucleus, where it regulates the expression of a diverse group of 
target genes that control essential cellular processes, including 
proliferation, differentiation, and apoptosis. Canonical Hippo 
transduction involves serine/threonine kinases mammalian 
STE20-like protein kinase 1/2 (MST1/2, which are homologs 
of Drosophila Hippo) (4, 5, 11, 12) and large tumor suppressor 
homolog 1/2 (LATS1/2) (7, 13, 14), which, in conjunction with 
adaptor proteins Salvador homolog 1 (SAV1) (12) and Mob 
kinase activator 1 (MOB1) (15), phosphorylate and inhibit the 
transcriptional co-activators Yes-associated protein 1 (YAP, a 
homolog of Yorkie) and transcriptional co-activator with PDZ-
binding motif (TAZ) [also known as WW domain-containing 
transcription regulator 1, WWTR1] (16). The Hippo pathway is 
“ON” when MST1/2 and LATS1/2 kinases are active. Through 
an interaction between the PPxY (PY) motifs of LATS1/2 and 
the WW domains of YAP and TAZ, activated LATS1/2 lead 
to phosphorylation of YAP and TAZ, which results in YAP/
TAZ cytoplasmic retention and β-TRCP (β-transducin repeat-
containing E3 ubiquitin protein ligase)-dependent proteasomal 
degradation (9, 10). When Hippo signaling is inactive or “OFF”, 
YAP and TAZ are localized to the nucleus, where they serve 
as transcriptional co-activators for TEA domain-containing 
sequence-specific transcription factors (TEADs) (17–21) as well 
as other transcription factors (16).
Regulation of the Hippo Pathway
Much of our understanding of Hippo regulation comes from 
studies performed in epithelial tissue. In this context, the 
transcriptional activities of YAP and TAZ are regulated by four 
interconnected inputs: (1) plasma membrane proteins, which 
complex with YAP and TAZ directly to sequester them at cell–cell 
junctions; (2) upstream adaptor proteins, which activate core 
Hippo kinases to ultimately phosphorylate and repress YAP and 
TAZ; (3) regulatory cross-talk from other signaling pathways; 
FiGURe 1 | Schematic representation of the mammalian Hippo 
signaling cascade. Canonical Hippo transduction involves MST1/2 and 
LATS1/2 kinases, which, in conjunction with SAV1 and MOB1, 
phosphorylate, and inhibit the transcriptional co-activators YAP and TAZ. 
Regulation of YAP and TAZ are governed by plasma membrane proteins, 
cytoskeletal adaptor proteins, regulatory cross-talk from other signaling 
pathways, and intrinsic and extrinsic mechanical cues with the actin 
cytoskeleton. For simplicity, not all the known protein–protein interactions 
and regulators of Hippo signaling are represented. When Hippo signaling 
is “OFF”, YAP/TAZ translocate to the nucleus to serve as transcriptional 
co-activators for TEADs as well as other transcription factors (only a few 
of which are represented here) involved in cellular proliferation, 
differentiation, self-renewal, and apoptosis. See text for additional 
details.
TABLe 1 | Pathway cross-talk with Hippo signaling.
Pathway cross-talk Reference
Developmental pathways
 Wnt/β-catenin (67–70)
 TGF-β (60, 61, 71–74)
 Notch (67, 75–77)
 Hedgehog (78–80)
MAP kinase related
 MAPK/Erk (81–83)
 GPCRs (29, 84, 85)
 SAPK/JNK (86, 87)
ErbB tyrosine kinases (88)
PI3K/mTOR/Akt (41, 89–91)
Jak/Stat (92, 93)
Ras (94–96)
Sox2 (97, 98)
MMP family (99)
Mevalonate pathway (100, 101)
Cellular metabolism (102, 103)
Epigenetic modification (104)
Cell cycle/CDK1 (105)
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and (4) intrinsic and extrinsic mechanical forces within the cell, 
which exert local control over YAP and TAZ localization. An 
overview of Hippo regulation is summarized below. For more 
detail, see the review by Grusche and colleagues (22), as well as 
three recent proteomic analyses that identified key protein–pro-
tein interactions with Hippo kinases, and YAP and TAZ within 
the global signaling network (23–25).
Regulation Through Plasma Membrane Proteins
Growth control is signaled through plasma membrane proteins 
to upstream Hippo proteins, often in response to increased 
cell density. The Crumbs polarity complex, other polarity 
proteins, and adherens junctions, which all modulate each 
other, contribute inputs to various Hippo components (22, 26). 
E-cadherin and the junction-associated Ajuba protein family 
modulate MST and LATS kinases, respectively. The Crumbs 
complex involves transmembrane proteins that recruit scaf-
fold proteins that localize to apical junctions and mediate cell 
polarity (27, 28). G-protein-coupled receptor (GPCR) ligands 
have been identified as regulators of Hippo signaling (29). 
Depending on the coupled G-protein, LATS1/2 kinases can 
either be activated or inhibited. YAP and TAZ directly influence 
the GPCR transcriptional activity, as YAP/TAZ are required 
for the expression of many GPCR-mediated target genes (29). 
The transmembrane hyaluronate receptor CD44 interacts with 
neurofibromin 2 (NF2, also known as Merlin) and other scaffold 
proteins to recruit LATS to the cell membrane, where it is phos-
phorylated (9, 30–32). Finally, the atypical cadherin protein Fat 
(Drosophila) is required for localization of Expanded (FRMD6 
in mammals) to apical junctions, which results in activation of 
Hippo (MST1/2) (33). In avian cells, FAT4 has been shown to 
inhibit YAP1-mediated neuroprogenitor cell proliferation and 
differentiation (34).
Regulation Through Upstream intracellular 
Adaptor Proteins
The core Hippo pathway is controlled by a complex upstream 
regulatory network. MST and LATS kinase activity are regulated 
by several upstream proteins, including Ras-association domain-
containing family proteins (RASSFs1-10) (35, 36), kidney and 
brain protein (KIBRA) (37–39), thousand and one amino acid 
protein 1 (TAO-1) (40), MAP/microtubule affinity-regulating 
kinase 1 (MARK1) (41), and NF2. Via their interaction through 
a homologous SARAH (SAlvador–RAssf–Hpo) binding domain, 
RASSFs and SAV1 regulate MST activity (42). MST1/2 complexes 
with SAV1 to directly phosphorylate LATS1/2. MST1/2 bound to 
SAV1 can also bind to and phosphorylate MOB1, which binds 
LATS1/2 to promote autophosphorylation. While a growing 
inventory of functional interactions between upstream proteins 
and Hippo kinases are well described, the degree to which their 
binding is dependent on tissue type or cellular context, as well 
as their reliance on canonical Hippo signaling, requires further 
investigation. Several of the aforementioned proteins can also 
directly alter YAP activity in a manner independent of MST and/
or LATS kinases (31, 43).
The Hippo pathway plays a major role in arbitrating cell con-
tact inhibition, cell proliferation, and promoting apoptosis (44). 
As cells increase in confluence, the tumor suppressor NF2 local-
izes near cell junctions to activate Hippo signaling (45, 46). YAP 
suppression has been shown to rescue the hyperproliferative 
phenotypes caused by NF2 inactivation in both mesothelioma 
(47) and meningioma (48). Furthermore, overexpression of a 
dominant-negative TEAD suppressed the tumor growth resulting 
from liver-specific NF2 deletion in mice (49). A negative feedback 
loop between YAP/TAZ and LATS2 has also been described. 
YAP and TAZ stimulation and TEAD binding induces LATS2 
expression, both directly and by inducing NF2 (50). In addition, 
YAP and TAZ may negatively regulate each other. For example, 
Taz accumulates in the livers of Yap knockout mice, while either 
in vitro suppression or overexpression of Yap results in inverse 
changes to Taz protein expression (50).
Regulation Through Cross-Talk with Other 
Pathways
Cell status and function, as well as overall tissue and organismal 
growth, is governed by an integrated network of morphogenic 
signals. Hippo transduction is proving to be a hub for such 
integration (51–53). Although studies are needed to clarify 
intra-pathway cross-talk in sarcomas, many of these pathways 
have been individually implicated in sarcomagenesis. YAP and 
TAZ are well recognized as co-activators for transcription fac-
tors of numerous signaling cascades. The specific ways in which 
signaling networks synergize or antagonize Hippo to coordinate 
biologic activity is only beginning to be understood. We highlight 
a few examples of regulatory cross-talk and refer to the studies 
referenced in Table 1 for additional details.
One example is illustrated by the relationship between the 
WNT and Hippo pathways. WNT activity is critical in myogen-
esis (54) and osteogenesis (55), and has recently been shown to 
be important in sarcomagenesis as well (56, 57). Rosenbluh et al. 
performed genome-scale loss-of-functions screens on 85 cancer 
cell lines (including osteosarcoma) and determined that WNT-
active cancers are dependent upon β-catenin forming a complex 
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with YAP and the transcription factor TBX5 to promote tran-
scription of anti-apoptotic genes that are essential for cancer cell 
transformation and survival (58). This relationship was validated 
in a β-catenin-derived orthotopic colon cancer murine model, 
where Yap was required for tumor formation (58). In another 
study using murine cardiac muscle, knockdown of Hippo compo-
nents Sav1, Mst1/2, or Lats2 results in increased Yap activity and 
cardiomyocyte proliferation with phenotypic cardiomegaly. Gene 
profiling from these mice reveal an elevated WNT signature, and 
the phenotypic effects could be offset by conditional loss of one 
β-catenin allele (59).
TGFβ and Hippo signaling also collaborate to direct cell 
behavior. YAP and TAZ associate with SMADs to promote 
transcription of TGFβ and BMP target genes (60–62). TGFβ 
signaling alters YAP/TAZ expression to drive mesenchymal stem 
cell (MSC) fate. For example, treatment of MSCs with BMP2 
leads to increased TAZ expression and enhanced interaction 
with RUNX2 to promote osteoblast differentiation (63). Notch 
and Hippo signaling provide another example of coordinated 
cross-talk. Notch has been shown to be a driver of both bone and 
soft-tissue sarcomas (64–66). While no studies have examined 
the interplay of Notch and Hippo in sarcomas, overexpression 
of Yap1 in mouse intestinal epithelia stimulates Notch signaling 
and the expansion of undifferentiated progenitor cells. However, 
treatment with γ-secretase inhibitors to block Notch signaling 
prevents the intestinal dysplasia caused by YAP (67). Together, 
these insights provide a deeper appreciation for the complex 
molecular circuitry that regulates Hippo activity in cell biology 
and malignancy.
Cytoskeletal Regulation Through Mechanical 
influences
To sustain proper function, from facilitating organ development 
during embryogenesis to maintain homeostasis postnatally, 
cells must perceive their microenvironment and respond 
appropriately to stimuli. In addition to transmitting biochemi-
cal signals, cells also extract information from mechanical cues. 
Mechanotransduction is the ability to perceive and translate 
physical stimuli [elasticity of the extracellular matrix (ECM) 
and forces exerted by cell–cell or cell–matrix interactions] into 
biochemical signals on a cellular level. Cells adapt to changes in 
tension through rapid cytoskeletal remodeling (106–108). YAP 
and TAZ have emerged as dynamic factors linking remodeling to 
nuclear transcriptional outputs that control cell behavior. Thus, 
by modulating YAP/TAZ activity, mechanical stimuli can direct 
cell fate and guide stem cell maintenance, proliferation, and 
differentiation (107, 109–111). For example, in Drosophila, the 
tension modulated within the cytoskeleton causes proportionate 
changes in wing growth through an Ajuba-Warts (homolog of 
LATS) complex (112).
In  situations of high mechanical stress and low cell conflu-
ence, YAP and TAZ are transcriptionally active, resulting in 
proliferation and tissue growth. However, with increasing cell 
contact, adhesion molecules stimulate LATS activity, result-
ing in YAP/TAZ phosphorylation and nuclear exclusion (44). 
Both F-actin polymerization and stress fiber formation lead to 
the nuclear localization and activation of YAP/TAZ, whereas 
disrupting F-actin inhibits YAP/TAZ transcriptional activity 
(113–116). As shown in Figure 2, ECM stiffness and cell shape/
spreading can also regulate YAP/TAZ localization by regulating 
the activity of Rho-GTPases and the formation of stress fibers 
and actin bundles (106, 110, 113). In MSCs, YAP and TAZ act as 
both sensors of mechanotransduction and mediators of cellular 
responses to mechanical signals (117, 118). YAP and TAZ remain 
inactive in the cytoplasm and direct MSCs to differentiate into 
adipocytes when human MSCs are exposed to low ECM stiffness, 
are cultured on a soft matrix, or are manipulated into a small 
round shape. However, YAP and TAZ are active in the nucleus 
and MSCs differentiate into osteoblasts when they are subjected 
to high ECM stiffness, are grown on a stiff matrix, or are stretched 
and manipulated into a “spread-out” morphology (119, 120). This 
mechanical control over YAP/TAZ activity supersedes density 
cues from cell–cell or cell–matrix contact (113, 115).
Interestingly, manipulation of YAP/TAZ expression can 
overrule mechanical influences to direct differentiation. When 
YAP/TAZ is suppressed, MSCs grown on a stiff ECM will 
undergo adipogenic differentiation. However, when activated 
YAP is overexpressed, MSCs grown on a soft ECM will undergo 
osteogenic differentiation (113). Knockdown of LATS1/2 has 
almost no effect on YAP/TAZ regulation by mechanical cues, 
and LATS-insensitive TAZ still responds to mechanical cues 
(113). Therefore, cellular mechanical stress can directly impact 
proliferation and tissue growth through YAP/TAZ, independent 
from Hippo signaling. Together, these studies emphasize the 
importance of cytoskeletal regulation of YAP and TAZ transcrip-
tional activity, and demonstrate that YAP and TAZ are required 
for mechanical signals to direct MSC fate.
Summary of Hippo Regulation
In summary, while the mechanistic and functional interactions 
between Hippo signaling and other regulatory pathways and 
cellular processes are not entirely understood, it is apparent that 
Hippo transduction links cell density and cell contact cues to 
morphogenic signals that regulate cell behavior. During develop-
ment and tissue regeneration, the tumor suppressor function of 
Hippo signaling serves to offset the proliferative effects of other 
pathways. However, during malignant transformation, Hippo 
transduction is suppressed as cells evade contact inhibition, 
allowing the downstream effectors, YAP and TAZ, to co-activate 
TEADs as well as other transcription factors, to promote pro-
proliferative and anti-apoptotic properties.
Hippo Signaling in Mesenchymal Stem 
Cell Fate
While the precise cellular origin for most sarcomas remains 
uncertain, they are presumed to arise from mesenchymal precur-
sors that fail to undergo terminal differentiation. These precursors 
have stem-like characteristics, including high proliferative and 
self-renewal potential. Therefore, insight into MSC regulation, 
lineage commitment, and differentiation (121), may shed light 
on sarcoma biology. As shown in Figure  2C, sarcoma subtypes 
are histologically described by the features of their presumed 
mesenchymal lineage. Summarized below are the known roles 
FiGURe 2 | Mechanical and physical influences on MSC cell fate. Cell 
geometry and ECM stiffness regulate MSC lineage commitment into neurons, 
adipocytes, skeletal muscle cells, or osteoblasts. (A) Increasing ECM stiffness 
in vitro (by increasing type I collagen concentration and crosslinking) 
compromises tissue organization, inhibits apoptosis and lumen formation, and 
destabilizes adherens junctions. Through modeling different ECM elasticities 
in vitro, MSCs differentiate into the varying lineages at elasticities that 
recapitulate the physiological ECM stiffness of their corresponding natural niche 
(shown as colored lines, with peaks indicating maximal differentiation). Pa, 
Pascal. (B) When MSCs are either cultured on a soft matrix or are manipulated 
into a small round shape, YAP/TAZ remain inhibited in the cytoplasm and 
MSCs differentiate into adipocytes. However, when MSCs are either grown on 
a stiff matrix or stretched and manipulated into a “spread-out” morphology, 
YAP/TAZ localize to the nucleus as MSCs differentiate into osteoblasts. 
(C) Corresponding histologic sarcoma subtype [2013 WHO classification 
(230)], which may reflect varying lineage differentiation from mesenchymal 
progenitor cells. This represents only a theoretical link between 
mechanotransduction influencing mesenchymal progenitors and sarcoma, and 
not all sarcoma subtypes are represented. Figures (A,B) are modified with 
permission from Halder et al. (108) and Piccolo et al. (117).
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of Hippo signaling in modulating normal bone (osteogenic), fat 
(adipogenic), and muscle (myogenic) development, which are 
the origins of the most common sarcomas. YAP/TAZ are also 
critical mediators of cancer stem cell biology, a topic reviewed by 
others (122).
Hippo Signaling in Osteogenic Differentiation
Osteogenic differentiation is coordinated by the transcrip-
tion factor, RUNX2, and a host of co-regulators (123), which 
activate the expression of osteoblast-specific genes, including 
osteocalcin (63, 124, 125). Through direct binding of the TAZ 
WW domain to the PY motif on RUNX2, TAZ has been identi-
fied as a transcriptional co-activator of RUNX2. Expression of 
an active TAZ mutant enhances RUNX2-driven gene expression 
two to threefold (63, 126), while knockdown of TAZ in MSCs 
inhibits osteogenesis when the cells are cultured under conditions 
favoring osteoblast differentiation (63). Transgenic mice with 
osteoblast-specific overexpression of Taz have significantly higher 
whole body bone mineral density, increased bone formation, 
and higher expression of RUNX2, osteocalcin, ALP, and osterix 
(127). TAZ-mediated osteogenesis may also occur downstream 
of the WNT pathway, since WNT3A can cause PP1A-mediated 
TAZ dephosphorylation, leading to TAZ nuclear localization and 
induction of osteogenic differentiation (68).
While the role of TAZ in supporting osteogenesis is clear, the 
role of YAP is more complex. When an activated YAP mutant was 
overexpressed in MSCs, osteogenic differentiation was promoted 
over adipogenic differentiation, even under conditions favoring 
the latter (113). However, YAP can also act as repressor of RUNX2 
when it is regulated by non-canonical pathways (128). For exam-
ple, when Src/Yes tyrosine signaling is inhibited, Yap tyrosine 
phosphorylation is blocked, Yap dissociates from RUNX2, and 
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osteocalcin is induced (128, 129). Last, there is evidence that 
YAP is a direct target of SOX2, a transcription factor important 
for MSC cell fate; in situations of high SOX2 or YAP expression, 
osteogenesis is blocked, while depletion of either SOX2 or YAP 
enhances osteogenesis (98).
In addition to YAP/TAZ, there is evidence that upstream 
scaffold proteins influence osteogenesis. Rassf2 knockout mice 
develop bone-remodeling defects, and in vitro studies show that 
ablation of RASSF2 suppresses osteoblastogenesis while promot-
ing osteoclastogenesis (130).
Hippo Signaling in Adipogenic Differentiation
A key transcription factor orchestrating adipogenesis is per-
oxisome proliferator-activated receptor gamma (PPARγ), which 
contains a PY motif for binding the WW domains on YAP and 
TAZ (63). In this context, binding of TAZ has an inhibitory 
role, suppressing transcriptional activity. When cultured under 
conditions that promote adipogenic differentiation, knockdown 
of TAZ permits MSCs to differentiate toward this lineage (63). 
Similarly, treatment with the small molecule KR62980 (a ligand 
for PPARγ that antagonizes adipocyte differentiation) does so by 
promoting TAZ nuclear localization and enhanced interaction 
between TAZ and PPARγ (131).
Recent work has shed light on the role of YAP in adipogenesis. 
Similar to osteogenesis, YAP is downstream of SOX2. However, 
YAP levels must be fine-tuned; both over or under-expression 
of YAP inhibits adipogenesis. Mechanistically, YAP induces the 
Wnt antagonist Dkk1 to diminish osteogenic signaling in favor 
of adipogenesis. In addition to YAP and TAZ, upstream Hippo 
regulators have been implicated. The Hippo adaptor protein 
SAV1 contains WW domains that can interact with the PY motif 
within PPARγ (132). MST1/2 stimulated SAV1 to bind PPARγ, 
which stabilizes and increases PPARγ levels, ultimately leading 
to adipogenic differentiation. In addition, knockdown of MST1/2 
or SAV1 results in the inhibition of adipogenesis (132), though 
it is not known whether this effect is through canonical Hippo 
transduction or an alternate pathway.
Hippo Signaling in Myogenic Differentiation
Myogenic differentiation is driven by the myogenic regulatory 
factor family [MRFs: MyoD, myogenin, MRF4, and myogenic 
factor 5 (Myf5)]) (133–135) in coordination with myocyte-specific 
MEF2 enhancer factors (136, 137). In murine C2C12 skeletal 
muscle myoblasts, YAP supports an undifferentiated phenotype 
and promotes myoblast proliferation (138–140). Upon differentia-
tion, nuclear YAP is translocated to the cytoplasm, with a 20-fold 
increase in YAP phosphorylation. Overexpression of YAP S127A, a 
mutant that cannot be phosphorylated at the LATS-regulated site, 
impedes myotube formation, and alters the expression of MRFs 
(139). Activation of YAP causes upregulation of Myf5, which pro-
motes myoblast proliferation. Activated YAP also leads to down-
regulation of MyoD and MEF2, which are important in cell-cycle 
exit and differentiation, as well as upregulation of inhibitors of 
MyoD and MEF2, such as ID2, Twist1, and Snai1/2 (133, 138). 
In activated satellite cells, which are resident stem cells of skeletal 
muscle, high YAP activity prevents differentiation and promotes 
proliferation (138, 140). YAP suppression dramatically reduces 
satellite cell-derived myoblast proliferation (140). Additionally, 
muscle CAT (MCAT) elements, which are TEAD-binding sites, 
are found in the promoters of genes that are selectively expressed 
in terminally differentiated skeletal muscle (140, 141).
Interestingly, while YAP inhibits myogenic differentiation, 
some studies suggest TAZ may enhance myogenesis. TAZ 
physically binds MyoD to enhance binding to the myogenin gene 
promoter to activate MyoD-dependent gene transcription (142, 
143). Ectopic overexpression of TAZ in C2C12 myoblasts results 
in accelerated myofiber formation, whereas TAZ loss lessened 
myogenic differentiation (142).
Evidence of upstream Hippo pathway regulators in muscle 
differentiation is limited. However, MST was found to have a 
pro-differentiation role during an investigation of caspase 3 in 
myogenesis (144). While caspases are classically known for their 
role in apoptosis, non-apoptotic functions have been reported. 
This appears to be the case in myogenesis, as caspase 3 was 
robustly activated in differentiating myoblasts without inducing 
apoptosis. Caspase 3-deficient myoblasts or C2C12 cells treated 
with caspase inhibitors are less able to differentiate, in part due 
to caspase 3-mediated regulation of MST1. Additionally, MST1 
is a substrate for caspase 3, and cleaved MST1 was enriched in 
myoblasts undergoing differentiation. In caspase 3-deficient myo-
blasts, introduction of the cleaved MST1 induced myogenic dif-
ferentiation, proving a link between these two pathways. However, 
MST1 activation must be tightly controlled, as MST1 activation in 
wild-type myoblasts ultimately led to cell death (144). While this 
study suggests a role for MST1 in myogenic differentiation, con-
nections between MST1 activation by caspase 3 and the canonical 
Hippo pathway in muscle remain to be determined.
The Molecular Basis for Hippo Signaling in 
Sarcomas
Sarcomas comprise a group of clinically and histologically diverse 
tumors of mesenchymal origin. They can develop anywhere in the 
body, with about half arising in bone and half in soft tissues. In 
children and adolescents, osteosarcoma (OS) and Ewing sarcoma 
(EWS) are the two most common malignant bone sarcomas, 
while rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma 
soft-tissue sarcomas (NRSTSs) are the major classes of malignant 
soft-tissue sarcomas (145).
As reviewed earlier, Hippo signaling is essential for proper organ 
growth, amplification of tissue-specific progenitor cells during tissue 
regeneration, and cellular proliferation (10, 146). In 2007, Dong and 
colleagues generated a liver-specific conditional Yap1 transgenic 
mouse model that develops hepatocellular carcinoma (10). This led 
to the understanding that YAP is important in cancer and identified 
Hippo signaling as a tumor suppressor pathway in mammals. In 
other genetically engineered mouse models (GEMMs), mutations 
or altered expression of Hippo pathway genes gives rise to sarco-
mas, substantiating Hippo pathway deregulation in sarcomagenesis 
(138, 147–149). The next section will review the molecular basis 
of dysregulated Hippo signaling in bone and soft-tissue sarcomas. 
Each subsection will highlight the pro-tumorigenic role of YAP/
TAZ, with subsequent cataloging of other Hippo pathway member 
involvement. Table 2 summarizes these alterations.
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Hippo Signaling in Osteosarcoma
Osteosarcoma is the most common primary malignancy of 
bone, with a 5-year overall survival of 60–70% (150). Given its 
decreased radiosensitivity compared to other sarcomas, surgical 
resection with chemotherapy is the mainstay of treatment. OS 
tumors are characterized by complex genomic rearrangements as 
well as copy number variations (151, 152). Mutations or loss-of-
function of tumor suppressors RB1 and TP53 are two of the most 
common genetic alterations and are reported in ~50 and ~30% 
of tumors, respectively (151). Aberrations in Hippo signaling are 
proving to be important in the biology of OS.
YAP
Human tissue microarray analyses have revealed high YAP1 pro-
tein expression in OS compared to surrounding non-cancerous 
tissue, and expression correlates with staging (153). These 
findings corroborate other studies which showed high YAP1 
expression in 78% of human OS samples and an increase in Hippo 
pathway target genes (80, 97, 154). Nuclear localization of Yap 
was found in Kios-5 murine OS cell lines, and Yap (and Taz, to a 
lesser extent) protein expression was also increased. In vitro sup-
pression of Yap was associated with decreased cell proliferation 
and invasion, as well as decreased expression of Runx2, CyclinD1, 
and MMP-9. Decreased tumor growth was observed with in vivo 
Yap suppression in murine xenografts (155), as well as transgenic 
mouse models (80).
The mechanism of YAP upregulation in OS is complex but 
appears to be due in part to the stem cell transcription factor 
SOX2. In murine OS cell lines, Sox2 was found to directly repress 
the Hippo pathway activators, Nf2 and Kibra, leading to increased 
YAP. When grown as osteospheres, where stem cells are enriched, 
YAP expression was higher (and Nf2 lower) compared to adher-
ent cells. In cells depleted of Sox2, either Yap overexpression or 
Nf2 suppression restored osteosphere formation. Conversely, 
suppressing Yap or overexpressing Nf2 promoted osteogenic 
differentiation and prevented osteosphere formation. The differ-
entiated phenotype of OS cells induced by Nf2 could be overcome 
by either overexpressing wild-type or constitutively active mutant 
Yap, but not mutant Yap with a deficient TEAD-binding site. 
This regulation of Yap by Sox2 occurs through canonical Hippo 
signaling, as suppression of either Mst1/2 or Lats1/2 abolished 
Nf2-induced osteogenic differentiation as well as changes in Yap 
expression and function (97).
YAP can also be upregulated by Hedgehog (Hh) pathway 
activation. Malignant OS occurs with high penetrance in 
Ptch1c/+;p53+/−;HOC-Cre mutant mice, in which Hh signaling 
is partially upregulated in a p53 heterozygous background. 
Resultant tumors have high Yap1 expression, which is significantly 
reduced with Hh inhibition, and suppression of Yap1 blocks 
tumor progression. This same study showed that the Hh-Yap axis 
may regulate the expression of H19, a maternally imprinted long 
non-coding RNA implicated in tumorigenesis (80).
RASSFs
Two RASSFs (RASSF5 and RASSF10) have been implicated as 
tumor suppressors in OS. Similar to other RASSF family mem-
bers, RASSF5 and RASSF10 are seen downregulated in human 
tumors (including OS) by CpG island promoter hypermeth-
ylation (156). In a human tissue microarray representing 45 OS 
samples, RASSF5 was significantly downregulated and expression 
negatively correlated with distant metastasis (157). In human 
U2OS cells, in vitro suppression of RASSF5 conveyed resistance 
to TNF-α-induced apoptosis, which is thought to occur through 
interaction and inactivation of the pro-apoptotic function of 
MST1 (158). Conversely, overexpression of RASSF5 in human 
OS cell lines decreases cell proliferation, increases apoptosis, and 
inhibits invasion.
NF2
In humans, germline or somatic mutations in one allele of NF2 
result in the disease neurofibromatosis type 2, which is associated 
with schwannomas, meningiomas, and ependymomas. However, 
mice heterozygous for Nf2 develop a variety of malignant tumors 
at high frequency, including OS (63%). Somatic mutations of the 
wild-type Nf2 allele were found in almost all of these tumors, 
implying that loss of heterozygosity of Nf2 may be required for 
sarcomagenesis (147).
CD44
CD44 is a cell-surface glycoprotein that transmits extracellular 
signals to the ERK, AKT, and Hippo pathways (82, 159). CD44 
was found to be suppressed by NF2, leading to decreased migra-
tion and invasion in OS cell lines in vitro, although an enhanced 
OS malignant phenotype was observed with knockdown of CD44 
in mice xenografts (160). Others have shown that NF2 mediates 
contact growth inhibition through ECM signals by complexing 
with CD44 (32).
MOB1
In vitro overexpression of MOB1A impairs cellular proliferation, 
while suppression of MOB1A leads to aberrant mitosis (15). In 
double-mutant mice lacking both Mob1A and Mob1B, complete 
loss of both alleles (Mob1AΔ/Δ1Btr/tr, null mutation of Mob1A, 
gene trap of Mob1B) is embryonically lethal. However, double-
mutant mice retaining one allele of either (Mob1AΔ/+1Btr/tr or 
Mob1AΔ/Δ1Btr/+) survive and spontaneously develop tumors with 
100% penetrance within 70 weeks. Extraskeletal OS arose in 24% 
(9/37) of mice, while benign exostosis occurred in 92% (34/37). 
All the tumors examined from either single heterozygote (Mob1
AΔ/+1Btr/tr or Mob1AΔ/Δ1Btr/+) group revealed loss of the wild-type 
Mob1 allele, suggesting loss of heterozygosity may be necessary 
for tumor growth (148).
Hippo Signaling in ewing Sarcoma
Ewing sarcoma is the second most common malignant bone 
tumor in children and young adults. Although the 5-year overall 
survival is about 70%, 30–40% of patients either present with 
metastatic disease or develop recurrence, where outcomes are 
worse (161). EWS is characterized by a t(11;22) chromosomal 
translocation, which generates a fusion gene encoding the EWS-
FLI1 chimeric protein that is thought to be the predominant 
driver of EWS tumorigenesis (162). The molecular basis for 
dysregulated Hippo signaling in EWS is beginning to be studied, 
as summarized below.
TABLe 2 | Proposed involvement of Hippo pathway components in sarcoma biology.
Sarcoma type Component Summary of proposed pathologic role Reference
Osteosarcoma YAP YAP1 expression is elevated and correlates with tumor staging and an increase in Hippo target 
genes
Suppression of YAP promotes differentiation, and decreases cell proliferation and tumor growth
YAP is a direct target of SOX2 in osteoprogenitors and YAP1 expression is altered by SOX2 
abundance
OS transgenic mice with upregulated Hedgehog signaling display high YAP1 expression
The long non-coding RNA H19 is aberrantly induced by YAP1 overexpression
(80, 153, 155)
RASSFs RASSF5 is downregulated in human OS tumors and expression negatively correlates with 
metastasis
In vitro overexpression of RASSF5 leads to decreased cell proliferation and invasion
RASSF10 promoter is epigenetically silenced through hypermethylation
(156–158)
NF2 NF2 expression is decreased and NF2 is shown to be a direct target of SOX2 in 
osteoprogenitors
63% of Nf2+/− mice develop OS. Increased penetrance and decreased latency and survival with 
Nf2+/−p53+/− mice. Both groups show loss of wild-type Nf2 allele
(97, 147, 160,  
198, 199)
MOB1 24% of Mob1AΔ/+1Btr/tr or Mob1AΔ/Δ1Btr/+ mice develop extraskeletal OS in 25–70 weeks (148)
Ewing sarcoma YAP In vitro YAP suppression decreases proliferation in EWS cells
BMI-1 stabilization of YAP is proposed to be a means for EWS cells to overcome 
contact-inhibition
(163)
RASSFs Hypermethylation of RASSF1A and RASSF2 occurs at high frequency and correlates with worse 
outcomes
(165, 166)
ERMS YAP YAP1 is elevated in human tumors and correlates with increased proliferation and clinical outcomes
Copy number gains of the YAP1 locus are reported
YAP suppression results in decreased proliferation and increased differentiation
Myf5- or Myod1-hYap1 S127A mice generate ERMS tumors within 4–8 weeks after Yap1 
S127A expression
100% of Pax7-hYap1 S127A mice generate ERMS-like tumors within 10–11 weeks after injury
(138, 178)
ARMS YAP YAP1 expression is increased in human tumor samples
In vitro suppression of YAP results in decreased proliferation and increased senescence
(138, 178)
RASSF4 RASSF4 is a PAX3-FOXO1 target gene
Overexpression of RASSF4 promotes cell proliferation
In vitro loss of RASSF4 leads to decreased cell growth
(178)
NRSTS YAP STSs display gene amplification and overexpression of YAP1 with increased  
TEAD-associated genes
YAP complexes with TEAD and the cell cycle transcription factor FOXM1 to support STS 
tumorigenesis
(186, 191)
RASSF1A RASSF1A hypermethylation is reported in ~20% of adult STSs and correlates with clinical 
outcomes
(189)
MST1/2 Hypermethylation of MST1 and MST2 occurs in 37 and 20% of STS, respectively (187, 200)
LATS1/2 Hypermethylation of LATS1 is associated with poorer prognosis and shorter survival times in 
human STS
(149, 188, 189)
60% of Lats1−/− mice die in utero but 14.3% of surviving female Lats1−/− mice develop 
fibrosarcomas by 4–10 months. Adding carcinogen exposure decreases latency and increases 
penetrance to 83%
Fibrosarcoma MOB1 22% of Mob1AΔ/+1Btr/tr or Mob1AΔ/Δ1Btr/+ mice develop fibrosarcoma in 25–70 weeks (148)
NF2 7% of Nf2+/− mice develop fibrosarcoma. 32% of Nf2+/−p53+/− mice develop fibrosarcoma (147)
EHE TAZ-CAMTA1
YAP-TFE3
TAZ-CAMTA1 and YAP1-TFE3 fusion proteins are pathognomonic findings in EHE tumor 
samples
(193–195)
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YAP
YAP suppression in human EWS cell lines decreases prolif-
eration and anchorage-independent colony formation (163). 
A relationship between YAP and BMI-1, a Polycomb complex 
protein involved in chromatin remodeling (164), has been 
proposed. In studies examining the effect of cell density in 
cultured EWS cells, loss of BMI-1 had no effect in low-density, 
while it caused cell-cycle arrest and death under conditions of 
confluence. These findings may be due in part to the role of 
BMI-1 in stabilizing YAP expression and activity, and may serve 
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as a means for BMI-1-driven EWS cells to overcome contact 
inhibition (163).
RASSFs
Hypermethylation of the promoter regions of RASSF1A and 
RASSF2 has been described in EWS and is correlated with worse 
clinical outcome (165, 166). One study of 55 human EWS tumors 
reported methylation rates for RASSF1A and RASSF2 of ~52 and 
~42%, respectively (165). In in  vitro studies, overexpression of 
either RASSF1A or RASSF2 in EWS cells reduced their ability to 
form colonies (165). In a separate study, methylation of RASSF1A 
was observed in 75% (3/4) of EWS cell lines and 68% (21/31) 
of human tumors (166), though these studies are contradicted 
by other reports that did not demonstrate increased RASSF1A 
hypermethylation (167, 168). The EWS-FLI1 fusion protein has 
recently been shown to provoke widespread epigenetic changes, 
including altered DNA methylation, although it is not known 
whether there is a direct effect on RASSF expression (168, 169).
Hippo Signaling in Rhabdomyosarcoma
Rhabdomyosarcomas are soft-tissue sarcomas and account for 
approximately 8% of all pediatric solid tumors (170). The two 
major histological subtypes are termed embryonal (ERMS) 
and alveolar (ARMS) rhabdomyosarcoma. ERMS, which is 
more common, typically arises in the head and neck or retro-
peritoneum of younger children and conveys a better prognosis 
(localized tumors have >70% 5-year overall survival) (171, 172). 
ERMS tumors demonstrate numerous chromosomal aberrations, 
including genomic amplifications, loss of heterozygosity of spe-
cific chromosomal regions, frequent chromosomal gains in 2, 8, 
12, and 13, and loss-of-imprinting (171–174). ARMS make up 
about 25–30% of cases and usually arise in the extremities or trunk 
and occur more frequently in adolescents. ARMS is characterized 
by recurrent chromosomal translocations, principally t(2;13) 
and t(1;13), which result in the expression of PAX3-FOXO1 and 
PAX7-FOXO1 fusion proteins, respectively (175). These aberrant 
chimeric proteins are oncogenic transcription factors that confer 
a poor prognosis (5-year overall survival <15% for metastatic or 
recurrent tumors) (173, 175–177). Interestingly, fusion-negative 
histologic ARMS have a cytogenetic and molecular profile similar 
to ERMS, and correspondingly similar clinical behavior (177).
YAP
YAP protein is upregulated in both ERMS and ARMS tumors 
(138, 178). In ERMS and fusion-negative ARMS, this is due in 
part to increased YAP1 locus copy number. The importance of 
YAP in ERMS was confirmed by the remarkable finding that 
expression of YAP S127A is sufficient for ERMS tumorigenesis 
in a GEMM (138). This finding was particularly surprising given 
prior work showing YAP1 S127A expression in adult mouse 
muscle caused atrophy (179). Similar to this study, limb stiffness 
and gait defects were the initial phenotypes observed in Myf5/
MyoD-YAP1 S127A mice (138). However, analysis of their 
muscle beds found that within the muscle damage were sites 
of active muscle regeneration and expansion of mononucleated 
cells. These were confirmed to be ERMS lesions, as they stained 
positive for ERMS histological markers. Tumor cells from these 
mice were transplantable, leading to secondary ERMS tumors 
with short latency. Given the high proportion of mononucleated 
cells in the primary tumor, Tremblay and colleagues hypothesized 
that satellite cells could serve as an ERMS cell of origin in this 
model. While expression of YAP1 S127A in the Pax7 (satellite) 
cell lineage did not induce ERMS formation, YAP1 S127A did 
transform satellite cells in the context of muscle injury. This sug-
gests that hyperactive YAP signaling in activated satellite cells has 
transformative properties.
Using this GEMM model, hyperactive YAP signaling in 
ERMS tumors was found to induce a myogenic differentiation 
block. When YAP S127A expression was reduced, tumors rapidly 
regressed, and tumor cells spontaneously expressed markers 
of terminal muscle differentiation. Similarly, endogenous YAP 
suppression in ERMS RD cell xenografts caused myogenic dif-
ferentiation (138). These findings are in line with earlier work 
implicating a role for YAP signaling in regulating myogenic differ-
entiation. In proliferating C2C12 and satellite cells, YAP levels are 
high and localized in the nucleus. Upon differentiation stimulus, 
YAP mRNA expression is reduced and YAP becomes cytoplasmic 
(139, 140). This suggests an important role for YAP signaling in 
maintaining a high proliferative and anti-differentiation state. 
Similarly, YAP S127A can block C2C12 and satellite cell in vitro 
differentiation. This differentiation block is believed to be due 
to transcriptional changes induced by YAP-TEAD, particularly 
through upregulation of pro-proliferative genes and repression 
of MYOD1 and MEF2 regulation of terminal differentiation 
genes (138).
Additional studies have supported a role for YAP in RMS. 
A subset of ERMS tumors harbor mutations in the PKN1 gene 
(encoding a kinase of the protein kinase C superfamily), which 
imparts a gene expression signature associated with activated 
YAP (180). In ARMS cells, in vitro genetic suppression of YAP 
induces growth arrest and senescence (178).
RASSF4
A role for the Hippo pathway in ARMS began with the identi-
fication of RASSF4 as a PAX3-FOXO1 target gene (178). Using 
transcriptional profiling studies, PAX3-FOXO1-expressing 
myoblasts were found to upregulate RASSF4 expression. Further, 
PAX3-FOXO1-positive ARMS cell lines and human tumors had 
elevated RASSF4 levels, and high RASSF4 expression was associ-
ated with worse RMS clinical prognosis. Loss-of-function studies 
demonstrated that RASSF4 was promoting cell proliferation and 
senescence evasion in ARMS cells. These RASSF4 functions were 
due to inhibition of MST1 signaling to MOB1. While no changes 
in signaling to LATS1 were observed, RASSF4-deficient ARMS 
cells did express lower levels of YAP1 protein. However, cells 
expressing a hyperactive YAP1 (YAP S127A) could not reverse the 
phenotypes associated with RASSF4 loss, suggesting an indirect 
connection between RASSF4 and YAP signaling (178). Altogether, 
these studies suggest that suppression of MST1-MOB1 signaling 
is an important oncogenic function of RASSF4 in ARMS.
TEAD-NCOA2 Fusions
NCOA2 is a transcriptional co-activator for steroid and nuclear 
hormone receptors. Fusion of TEAD to NCOA2 was found in 
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tumor tissue removed from a 4-week-old child with spindle 
cell RMS (181), a rare variant of ERMS (182). While NCOA2 
gene rearrangements with other gene partners are seen in high 
frequency in congenital spindle cell RMS and mesenchymal 
chondrosarcomas (181, 183), the clinical and molecular 
significance of TEAD as a binding partner in this case is not 
known.
Hippo Signaling in Non-Rhabdomyosarcoma 
Soft-Tissue Sarcomas
Non-rhabdomyosarcoma soft-tissue sarcomas comprise the fifth 
most common group of solid tumors in children, accounting 
for 8–9% of childhood malignancies. These are histologically 
heterogeneous tumors that share some biologic characteristics. 
Surgical resection results in remission for about 80% of patients 
presenting with localized disease, though survival for those with 
unresected or metastatic disease remains poor (184). Many 
NRSTS, particularly those common in children, are character-
ized by disease-defining chromosomal translocations. Examples 
include synovial sarcoma t(X;18) and alveolar soft part sarcoma 
t(X;17), which result in the SYT-SSX and ASPL-TFE3 oncogenic 
fusion proteins, respectively (145). Other NRSTSs that are more 
common in adults, such as leiomyosarcoma or undifferentiated 
sarcoma, display multiple complex karyotypic abnormalities 
with frequent mutations in the TP53 and RB tumor suppressor 
pathways (185).
YAP
Nuclear staining for YAP is increased in a subset of human STS 
samples, compared to corresponding normal connective tissue 
(186). KRAS-based [LSLKrasG12D/+;Tp53fl/fl (KP)] GEMMs were 
used to further investigate the role of YAP in STS. Yap sup-
pression in allograft tumors generated from KP cells results in 
decreased cell proliferation and tumor growth, and treatment 
with verteporfin to block the YAP–TEAD interaction decreased 
transcription of Yap1 target genes. Many of the downregulated 
mRNAs in this model were noted to also be targets of Foxm1, a 
transcription factor involved in cell-cycle progression. FOXM1 
is ordinarily inhibited by direct interaction with members of 
the TP53 and RB tumor suppressor pathways, and it is often 
overexpressed in malignancies where these tumor suppressor 
functions have been lost (186). FOXM1 expression was found 
to be increased in a variety of human sarcoma samples. In xeno-
graft studies, FOXM1 suppression inhibited sarcoma growth. 
Co-immunoprecipitation and ChIP-seq experiments reveal 
that FOXM1 physically associates with a YAP/TEAD complex 
(186). YAP suppression in human sarcoma cell lines resulted in 
decreased proliferation and decreased FOXM1 expression, sug-
gesting a novel role for YAP in co-activating FOXM1-mediated 
transcription in STS.
MST1/2
Hypermethylation of MST1 and MST2 promoters occurs in 
37 and 20% of all STS (including RMS), respectively (187). In 
leiomyosarcoma samples, hypermethylation of RASSF1A and 
MST2 were mutually exclusive, implying a common signaling 
pathway may exist for both genes. Surprisingly, methylation of 
the MST1 promoter appears to correlate with a decreased risk of 
tumor-related mortality (187), albeit from a retrospective cohort 
with a small sample size.
LATS
Reduced LATS gene expression was observed in 14% (7/50) of 
human adult STS tumors (188). These findings correlate with 
subtype, as three of four myxoid liposarcomas, three of seven 
leiomyosarcomas, and one of nine malignant fibrous histiocyto-
mas showed reduced or no expression of LATS1. In one of those 
samples, an allelic loss of the LATS1 locus in chromosome 6q23-
25.1, resulting from a missense point mutation, was observed. 
The other six samples showed aberrant hypermethylation of the 
putative LATS1 promoter (188), corroborating another study 
showing hypermethylation of the LATS1 promoter in 7% (3/43) 
of human STS samples (187). Hypermethylation of LATS1 in 
STSs is associated with a worse prognosis and shorter survival 
times (189). It is not known whether epigenetic regulation of 
Hippo pathway kinases alters the expression of YAP and TAZ.
In transgenic mouse models, most mice (60/101) homozygous 
for a null mutation in Lats1 died in utero or within post-natal day 
1. However, ~14% of surviving female Lats1−/− mice developed 
large NRSTS by 4–10  months of age consistent with fibrosar-
comas. After exposure to the carcinogen DMBA and repeated 
exposure to UVB, 83% (10/12) of Lats1−/− mice developed STSs, 
whereas no wild-type or heterozygous Lats1+/− mice developed 
tumors (149).
RASSF1A
Epigenetic silencing of RASSF1A via hypermethylation of its 
promoter occurs in 20% (17/84) of adult STSs (189). (This 
study included six cases of RMS, which did not reveal RASSF1A 
hypermethylation.) RASSF1A silencing was especially common 
in leiomyosarcomas, and overall was associated with an increase 
in tumor-related death.
VGLL3
Like YAP, VGLL3 is a TEAD co-activator and has been identified 
as an inhibitor of terminal adipogenic differentiation, suggesting 
that it has a core role in mesenchymal cell fate (190). In a study of 
404 adult STSs, recurrent amplifications of chromosomes 11q22 
and 3p12, which contain genes for YAP1 and Vestigial-like 3 
(VGLL3), respectively, were identified in 10% of cases. Genomic 
amplification corresponded to overexpression of YAP1 and 
VGLL3 at the message level, and an increase in TEAD-associated 
genes. In vitro suppression of YAP1 or VGLL3 decreased cell pro-
liferation and in the case of VGLL3, decreased migration (191). 
In a smaller study, analysis of eight NRSTS tumors identified 
3p11-12 as a commonly amplified region of a ring chromosome 
3 that was associated with high expression of VGLL3 (192).
TAZ-CAMTA1 and YAP-TFE3 Fusions
Fusions between the WWTR1 (gene name for TAZ protein) and 
CAMTA1 genes were first noted in a NRSTS subtype termed 
epithelioid hemangioendothelioma (EHE) (193). EHEs are vas-
cular sarcomas that can develop in bone, soft tissue, or visceral 
organs, and they demonstrate a clinical behavior intermediate 
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between benign hemangiomas and high-grade angiosarcomas. 
Sequencing of two tumors identified the t(1;3) translocation 
between WWTR1 and CAMTA1, and showed the fusion product 
to be under transcriptional control of the TAZ promoter. A larger 
study investigating 17 EHE tumors confirmed the translocation 
in all samples. The translocation and resulting transcript were not 
seen in epithelioid hemangioma and epithelioid angiosarcoma, 
morphologic mimics of EHE (194).
Subsequently, a YAP1-TFE3 fusion product was identified in 
nine EHE samples that were morphologically different from the 
WWTR1-CAMTA1 fusion-positive tumors (195). These findings 
were corroborated by two additional studies, the largest of which 
included 35 tumors and used a combination of IHC, FISH, and 
RT-PCR to validate WWTR1-CAMTA1 fusion events in 33 cases 
and YAP1-TFE3 protein in two cases (196, 197). The oncogenic 
role of these signature fusions in EHE, or the role of Hippo signal-
ing in vascular sarcomas, has not yet been established.
Targeting Hippo Signaling for Therapy
Recognition of the importance of Hippo signaling in malignancy 
has led to preclinical studies aimed at targeting components of this 
pathway for anti-cancer therapy. Modeled genetic manipulation 
of Hippo components exhibit profound effects on tumorigenicity, 
which provides optimism that modulators of Hippo components 
could be effective in patients. Indeed, the Hippo cascade involves 
many protein–protein interactions that could serve as novel tar-
gets. For details on each potential modulator, see recent reviews 
in Ref. (201, 202).
TABLe 3 | Pharmacologic modulators of the Hippo pathway.
Key Compound Mechanism References
A Fostriecin derivative Inhibits PP2A (210)
B FTY720 Activates PP2A (211)
C 9E1 Inhibits MST1 activity (212)
D C19 Activates MST/LATS (213)
E TM-25659 Modulates TAZ localization (214)
F Pyrrolidone 1 14-3-3 protein stabilizer (215)
G Verteporfin Inhibits YAP-TEAD interaction (49)
Cyclic YAP-like peptide Inhibits YAP-TEAD interaction (205)
VGLL4-like peptide Inhibits YAP-TEAD interaction (216)
ABT-263, TW37 Inhibit BCL-xL (a YAP target) (208, 217)
H Dasatinib Inhibits β-catenin-YAP-TBX5 complex (58)
I Epinephrine Activates LATS through GPCRs (29, 218)
Dobutamine Causes YAP phosphorylation (219)
J Phenoxodiol SPHK1 inhibitor (220, 221)
BrP-LPA LPA analog that blocks LPA receptors (222)
Thrombin Acts on PARS to activate YAP (223)
K LT3015 Sphingomab Monoclonal antibodies to LPA, S1P (224–226)
L Ibudilast Inhibits PDE (218, 227, 228)
M Statins HMG-CoA reductase inhibitors (100, 101)
N Y27632 RHO/ROCK inhibitors (113, 116, 229)
HA1077
Botulinum toxin C3
O Blebbistatin F-actin destabilizers (113, 115, 116)
Cytochalasin D (114–116)
Latrunculin A/B (113, 115, 116)
ML7 (115)
P WNT (or other pathway) modulators (see Regulation Through Cross-Talk with Other Pathways and 
Hippo Modulation to Augment Other Pathway-Directed Therapies)
Small Molecule Modulators of the  
Hippo Pathway
As listed in Table 3 and highlighted in Figure 3, several pharma-
cologic compounds, that directly or indirectly modulate Hippo 
pathway activity, have been identified. However, a number of 
important challenges exist. First, while kinases are often excel-
lent targets for small molecule inhibitors, the majority of kinases 
in the Hippo pathway are tumor suppressors, and restoring lost 
tumor suppressive function is not easily achieved. Moreover, and 
as highlighted here, aberrant hyperactivity of oncogenic YAP 
and TAZ is often seen in malignancy as a result of mutations in 
proteins from other signaling networks, even in the presence of 
intact upstream Hippo kinase activity. However, small molecules 
aimed at increasing YAP/TAZ phosphorylation-induced nuclear 
export and proteosomal degradation could be effective at reduc-
ing their activity.
As such, inhibiting the activity of YAP/TAZ is the most obvi-
ous and presumably the most potent anti-cancer approach. Three 
porphyrin-related compounds were identified as top hits in a small 
molecule library screen of potential modulators for inhibiting the 
transcriptional activity of YAP in vitro. Verteporfin is a photosen-
sitizer used clinically to treat patients with macular degeneration 
(203). Verteporfin binding to YAP alters YAP conformation to 
prevent it from binding to TEAD transcription factors. In vivo 
experiments in murine systems show verteporfin inhibits YAP-
induced liver overgrowth by decreasing cell proliferation (49). 
In vitro treatment of retinoblastoma cells with verteporfin caused 
decreased cell proliferation and down-regulation of the pluripo-
tency marker OCT4 (204). Other small molecule inhibitors, such 
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FiGURe 3 | Pharmacologic modulators of the Hippo pathway. The 
Hippo cascade involves many protein–protein interactions that could serve 
as novel targets, and numerous pharmacologic compounds either directly or 
indirectly modulate Hippo activity. Some of the compounds activate Hippo 
components and others have an inhibitory role. While not all referenced 
studies have proven that modulation of upstream regulators result in 
concomitant changes in YAP or TAZ activity, these provide proof of principal 
that targeting Hippo signaling could be harnessed as a novel strategy to 
treat sarcomas. This is not an inclusive list, and other compounds are known 
to modulate Hippo components. Figure is modified with permission from 
Park et al. (202). Letters in Red correspond to the letters in the Key in 
Table 3.
as cyclic YAP-like peptides and TM-25659, have been developed 
to interfere with YAP/TAZ–TEAD interactions (205).
Another challenge is that the Hippo pathway is ubiquitously 
expressed and thus, systemic treatment may cause detrimental 
side effects. This is particularly important in the pediatric popu-
lation, where normal growth and development in most tissues 
likely rely on intact Hippo signaling. Similarly, GPCRs, although 
relatively accessible to inhibition, have broad physiological func-
tions. However, intestine-specific conditional Yap1 knockout 
mice develop normally (206), implying that in some instances, 
YAP/TAZ may be dispensable for tissue development. YAP and 
TAZ are responsive to tissue-specific regulatory elements, pre-
senting a theoretical possibility of targeting Hippo signaling in 
specific cells or tissues.
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Conclusion
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However, genetic and epigenetic dysregulation of upstream core 
Hippo pathway members, and adaptor proteins has been noted. 
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